We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01603121
Recruitment Status : Terminated (Unable to enroll sufficient number of subjects)
First Posted : May 22, 2012
Results First Posted : August 18, 2016
Last Update Posted : August 18, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The primary goal of the study is to investigate the safety and tolerability of the investigational drug lisofylline, when administered under the skin or in the vein, in people with type 1 diabetes. A second aim is to determine how much drug is available in the blood after injection under the skin, compared to injection in the vein.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: Lisofylline Phase 1 Phase 2

Detailed Description:

This is an open-label, randomized, crossover study in subjects with type 1 diabetes. There are two treatment periods separated by approximately one week. One treatment will consist of a 10 hour subcutaneous infusion of lisofylline, and the other treatment will consist of a 10 hour intravenous infusion of lisofylline.

Eligible subjects will be admitted to the Infusion Center the morning of dosing (Day 1, Day 7) during each treatment period, receive their assigned dose of study drug on Day 1 and Day 7, and will remain confined to the Infusion Center until approximately 3 hours following the start of study drug administration for the remaining blood draws. The subjects will then be escorted to the Sleep Center of Eastern Virginia Medical School for an overnight stay during which time their heart rate and oxygen saturation will be monitored by pulse oximetry. The next morning the subjects will return to the Infusion Center for a final blood draw and physical examination. The Infusion Center and the Sleep Disorders Center are both within Sentara Norfolk General Hospital.

All subjects will be assigned to a treatment sequence according to a randomization schedule.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (9 mg/kg) Administration in Subjects With Type 1 Diabetes Mellitus
Study Start Date : February 2012
Primary Completion Date : May 2013
Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Lisofylline subcutaneous
Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
Drug: Lisofylline
Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
Experimental: Lisofylline intravenous
Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
Drug: Lisofylline
Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.

Outcome Measures

Primary Outcome Measures :
  1. Safety and Tolerability of Study Drug [ Time Frame: 1 month ]

    Subjects will be monitored for adverse events both during and after the study drug infusion and will undergo physical examinations, electrocardiograms and clinical safety laboratory tests.

    Study staff will contact subjects within 5 days after each dosing period and approximately 30 days after the 2nd dosing period, to review laboratory results and to ask the subject about any changes in health that they have experienced. Should the subject require an in-person evaluation, this will be arranged with the principal or sub-investigator promptly.

Secondary Outcome Measures :
  1. Study Drug Bioavailability After Subcutaneous and Intravenous Infusion [ Time Frame: 24 hours ]
    Blood will be collected for determination of lisofylline concentrations at various predetermined time points during the infusions, and 10 and 24 hours following infusion completion. This will help to determine if subcutaneous infusion over 10 hours results in similar lisofylline plasma concentrations as with intravenous infusion.

  2. Evaluation of Early Efficacy of Study Drug [ Time Frame: 24 hours ]
    Blood draws will be performed at predetermined time points during and after the infusions in order to measure serum cytokine and chemokine concentrations, as well as to measure plasma STAT 4 and phosphorylated STAT 4 (markers of lisofylline efficacy).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female adults between the ages of 18 and 45 years of age
  • Ability to understand and provide written informed consent
  • Ability to complete the study in compliance with the protocol
  • If female, subjects must be non-pregnant and non-lactating, and willing to use appropriate and adequate contraception during the study
  • If male, subjects must be willing to use effective birth control during the study
  • Weight at least 50 kgs (110 lbs)
  • Body mass index between 18.5 and 30 kg/m2
  • QTc < 450 msec at screening
  • Clinical diagnosis of type 1 diabetes at least 2 years prior to screening
  • Treatment with insulin for at least 1 year and on a stable dose for at least 3 months prior to screening (dose must be < 0.8 units/kg/day)
  • Subjects must self-monitor blood glucose levels at least daily
  • HbA1c 6-9%
  • Serum c-peptide level < 0.6 ng/mL
  • Serum creatinine < 1.5 mg/dL for males and < 1.4 mg/dL for females
  • Negative hepatitis B, hepatitis C and HIV testing at screening or within 3 months of screening
  • Subjects must be free from clinically significant abnormal findings at the time of screening (to include abnormalities on examination, medical history, electrocardiogram, clinical laboratory testing); to be determined by principal investigator

Exclusion Criteria:

  • Subjects with significant stomach, liver, kidney or heart disease, including high blood pressure, stroke or other blood vessel disease. Significant eye problems due to diabetes, diabetic nerve disease, or non-healed diabetic foot ulcers
  • Personal or family history of long QTc syndrome
  • History of clinically significant changes in orthostatic blood pressure
  • Clinically significant changes in orthostatic blood pressure at screening
  • History of peptic ulcer disease and/or gastrointestinal bleeding/perforation
  • History or presence of proliferative retinopathy, severe non-proliferative retinopathy, macular edema or presence of untreated diabetic eye disease
  • History of severe peripheral or autonomic neuropathy in the opinion of the study physician
  • History of hypoglycemia unawareness, and/or episodes of severe hypoglycemia within 60 days of screening
  • Diagnosis of type 2 diabetes, based upon subject report
  • Use of oral antihyperglycemic medications, pentoxyifylline, and/or theophylline
  • Use of any drug therapy that directly affects gastrointestinal motility
  • History of any significant drug allergy
  • History of difficulty with phlebotomy
  • Use of any recreational drugs within the past year or a previous history of drug or alcohol abuse
  • Positive results from a screen for alcohol or substances of abuse at screening or upon admission to the study site
  • Current smoker or user of any tobacco products
  • Use of prescription medications is acceptable at the Principal Investigator's discretion if they have been part of a stable drug regimen documented for the last 60 days. Drug therapy should be held the morning of Day 1 and Day 7 at the Principal Investigator's discretion
  • use of any over-the-counter drugs or herbal preparations within 72 hours prior to receiving study drug
  • Consumption of any caffeine-containing foods or beverages within 24 hours prior to receiving study drug
  • Consumption of alcohol within 24 hours prior to admission to the study site
  • Consumption of any grapefruit or grapefruit-containing juices within 72 hours prior to receiving study drug
  • Use of an investigational drug or product, or participation in a drug research study within 30 days prior to receiving drug
  • Prior exposure to lisofylline
  • Donation of blood (1 pint or more) within 30 days or plasma within 7 days of receiving study drug
  • Any condition which in the opinion of the study investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he or she took part in the trial
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01603121

United States, Virginia
Eastern Virginia Medical School Strelitz Diabetes Center
Norfolk, Virginia, United States, 23510
Sponsors and Collaborators
Eastern Virginia Medical School
Principal Investigator: David C Lieb, MD Eastern Virginia Medical School
More Information

Responsible Party: David C. Lieb, MD, Dr., Eastern Virginia Medical School
ClinicalTrials.gov Identifier: NCT01603121     History of Changes
Other Study ID Numbers: DL-001
First Posted: May 22, 2012    Key Record Dates
Results First Posted: August 18, 2016
Last Update Posted: August 18, 2016
Last Verified: August 2016

Keywords provided by David C. Lieb, MD, Eastern Virginia Medical School:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Protective Agents
Vasodilator Agents
Free Radical Scavengers